ARGX
argenx SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
ARGX vs peer average
47/100
ARGX vs. peer average (C vs. C)
Grade spread
B 4 · C 5 · D 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
IMVT is the first available peer comparator.
Immunovant is a more direct FcRn competitor than broad large-cap pharma peers because its pipeline targets MG and CIDP with batoclimab and IMVT-1402; ARGX's premium depends on VYVGART maintaining commercial and dosing advantages as those programs mature.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ARGX
argenx SE
IMVT
Immunovant
Grade
C
C
Momentum
44
89
Value
59
41
Sentiment
52
39
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed
Grade position vs IMVT
ARGX / IMVT
Grade Position
In line
ARGX vs. peer average (C vs. C)
47/100
Momentum
44
IMVTValue
59
ARGXSentiment
52
ARGXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ARGX
IMVT is the first peer returned for this comparison set.